Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has achieved a significant breakthrough in heart valve treatment with the completion of three complex valve-in-valve (ViV) procedures using its innovative DurAVR™ transcatheter heart valve.
These procedures were under Health Canada’s special access program (SAP) which allows healthcare professionals to access unlicensed medical devices, such as DurAVR, for emergency use when conventional therapies have failed, are unavailable or are unsuitable to treat a patient.
The transcatheter ViV replacement is performed by implanting a transcatheter heart valve within a failing bioprosthetic aortic valve, a less invasive procedure compared with reoperative surgical aortic valve replacement.
"Great opportunity"
Dr Anita Asgar, who performed the procedures at Institut de Cardiologie de Montreal said: "The challenge we face as clinicians is the need to preserve coronary access, but these are also patients who are also reasonably active, and we need to give them a good haemodynamic result, we need to really improve their symptoms so they can have a good quality of life
“As a clinician, it’s a great opportunity to have access to a technology that may help us with what is probably going to be a tsunami of valve-in-valve procedures that we are going to have to do
"These patients are in a challenging situation and are in need of a better option than what is commercially available. DurAVR™ delivered an outstanding result with meaningful patient benefits".
About DurAVRTM
Anteris' lead product, DurAVR, is a transcatheter heart valve (THV) for treating aortic stenosis.
DurAVR THV was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons.
It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue.
This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.
It is made using ADAPT® tissue, Anteris’ patented anti-calcification tissue technology.
Anteris CEO Wayne Paterson said: “With an increasing number of bioprosthetic valves failing in patients it’s important that we study the effects of DurAVR™ in this patient population to better understand if the best-in-class results we see in newly treated aortic stenosis is also seen in this difficult to treat population.
"We are pleased with the results to date and will continue to study this group who have limited treatment options today.”